Patent ID: 11944689
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 7:
8. The Ligand Drug Conjugate compound of claim 5, wherein —O′-Su has the structure of:, wherein the wavy line represents covalent bonding of O′ to the remainder of the structure representing the Ligand Drug Conjugate compound: and R45 is —CH2OH or —CO2H, or a pharmaceutically acceptable salt thereof, or wherein
W is a Peptide Cleavable Unit comprised of a dipeptide wherein the C-terminus of the dipeptide is covalently bonded to J wherein the dipeptide provides for a recognition site for a regulatory or lysosomal protease for cleavage by said protease of the W-J bond within a Ligand Drug Conjugate so as to initiate release of D or D+ as a tubulysin or auristatin from that Ligand Drug Conjugate compound, wherein the dipeptide of W has the structure of:, wherein R34 is benzyl, methyl, isopropyl, isobutyl, sec-butyl, —CH(OH)CH3 or has the structure of, wherein the asterisk indicates the point of covalent attachment to the dipeptide backbone; and
R35 is methyl or —(CH2)3NH(C═O)NH2, or R35 is —(CH2)4—NH2, —(CH2)3NH(C═NH)NH2, or —(CH2)2CO2H, or a pharmaceutically acceptable salt thereof; and
wherein the wavy lines indicate the points of covalent attachment of the dipeptide into the structure representing the Ligand Drug Conjugate compound.